| HOME >> BIOLOGY >> TECHNOLOGY |
ACTIQ (63%) 49% (58%)
Generic OTFC 135% 0% 135%
FENTORA 362% 0% 362%
AMRIX 100% 0% 100%
Pain (25%) 49% (22%)
Other 23% 13% 15%
(2%) 18% 1%
* For the year ended December 31, 2006, amounts exclude the impact of the
DoD Tricare program reversal of $13.3 million which reduced GAAP U.S.
sales of PROVIGIL, GABITRIL and ACTIQ by $6.9 million, $0.9 million and
$5.5 million, respectively.
CEPHALON, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(In thousands, except share data)
(Unaudited)
December 31, December 31,
2007 2006
CURRENT ASSETS:
Cash and cash equivalents $818,669 $496,512
Investments 7,596 25,212
Receivables, net 276,776 270,045
Inventory, net 99,098 85,239
Deferred tax assets, net 176,619 184,518
Other current assets 43,267 47,278
Total current assets 1,422,025 1,108,804
PROPERTY AND EQUIPMENT, net 500,396 453,010
GOODWILL 476,515 467,167
INTANGIBLE ASSET
'/>"/>
| SOURCE Cephalon, Inc. Copyright©2008 PR Newswire. All rights reserved |